FEMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Femasys Inc (FEMY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive developments such as MDSAP certification for its FemBloc product, the financial performance and lack of strong trading signals suggest it is better to hold off on investing until clearer growth trends or stronger signals emerge.
The MACD is above 0 and positively contracting, indicating slight bullish momentum. RSI is neutral at 62.021, and moving averages are converging, showing no clear trend. Key resistance levels are at 0.578 and 0.606, while support levels are at 0.485 and 0.457.
The FemBloc product has received MDSAP certification, enhancing its regulatory capabilities and commercialization potential globally. The product addresses a significant global demand for non-surgical permanent contraception.
The company has declining financial metrics, including a 22.45% drop in net income YoY and a 58.33% drop in EPS YoY. Gross margin also declined by 7.50%, indicating potential profitability challenges.
In Q3 2025, revenue increased by 31.44% YoY to $729,394. However, net income dropped by 22.45% YoY to -$4,194,821, and EPS fell by 58.33% YoY to -0.1. Gross margin also declined to 47.97%, down 7.50% YoY.
No data available for analyst ratings or price target changes.
